If you are wondering whether Travere Therapeutics is still good value after its big rebound, you are not alone. This stock has quickly moved from recovery story to serious contender on many watchlists ...

Travere Therapeutics recently reached a new 52-week high after investors reacted to regulatory updates for its rare kidney disease therapy FILSPARI, including the removal of an FDA advisory committee ...

As of Wednesday, December 24, Travere Therapeutics, Inc.’s TVTX share price has surged by 17.75%, which has investors questioning if this is right time to sell.

The stock of commercial-stage biotech Travere Therapeutics (NASDAQ: TVTX) barreled into the late holiday period in style. On ...

According to TipRanks.com, Divan is a 5-star analyst with an average return of 10.3% and a 55.4% success rate. Divan covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, ...

Browse investing articles and stock analysis by Eric Volkman. Get expert financial insights and investment advice from The Motley Fool.

Rafael Kramann, MD, PhD, FASN, FERA, embraced the field of nephrology early in his career for the opportunity to take on ...

Finerenone use for 6 months was safe and associated with a significant 25% decrease in albuminuria for adults with type 1 diabetes and chronic kidney disease, according to data presented in the ...

SAN DIEGO, December 11, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted ...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron ...

Travere Therapeutics Inc. has reached a significant milestone, with its stock hitting a 52-week high of 37.12 USD. This achievement underscores a remarkable year for the company, marked by a ...

Eric Dube, President and CEO, Travere Therapeutics: Yeah, I think there’s certainly an anticipation. I think we’re going to need to see, you know, the pricing there. We’re going to need to see what ...